Global Antibody Discovery Market is valued approximately USD 6.9 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 9.7% over the forecast period 2023-2030. Antibody discovery is the process of identifying and developing antibodies that can specifically recognize and bind to target molecules, such as proteins or pathogens, in the human body. Antibodies are Y-shaped proteins produced by the immune system in response to the presence of foreign substances, known as antigens. The goal of antibody discovery is to generate antibodies that can be used for various purposes, including diagnostics, therapeutics, and research tools. These antibodies can be designed to selectively bind to a specific target, such as a cancer cell marker, a viral protein, or a receptor on a cell surface. The Antibody Discovery market is expanding because of factors such as increase in investment in R&D activities of antibody discovery and surge in prevalence of infectious & chronic diseases. According to the World Health Organisation (WHO), low- and middle-income nations would account for 77% of fatalities from chronic diseases in 2021. As a result, the rise in the prevalence of chronic diseases has raised the necessity for producing high-quality antibodies. In addition to these, The Journal of Biomedical and Environmental Science estimates that in China, 330 million individuals would have cardiovascular disease in year 2021. Additionally, the American Cancer Society reports that in 2020, there were around 1.8 million new cancer cases diagnosed and 606,520 cancer deaths reported in the United States. In addition, the market is expanding as a result of increased R&D investments in antibody discovery and the rise in demand for better, more affordable, and more effective treatments for a number of diseases. Antibodies offer a promising approach to treating diseases since they may be altered to target specific infections and can be administered with little adverse effects. To promote the development of rapid antibody discovery, Abzena, a leading provider of biologics and antibody drug conjugates, announced in September 2022 that it will increase its research and development capacity in Cambridge. Moreover, increased awareness of personalized medicine among consumers and rise in funding for research and development centers is creating a lucrative opportunity to the market. However, high cost of antibody discovery hampers the market growth throughout the forecast period of 2023-2030. The key regions considered for the Global Antibody Discovery Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to prevelance of diseases in the region, dominance of key market players and rising number of research and development activities in the region. Asia Pacific is expected to grow significantly during the forecast period, owing to factors such as rising disease prevelance and target populations, an increase in the number of collaborations for discovery activities, geographic expansion of key players, and active participation of government and nonprofit organizations in the market space. Major market player included in this report are: Fairjourney Biologics S.A Biocytogen Pharmaceuticals Co Ltd Genscript Technology Corporation Danaher Corporation Creative Biolabs Inc. Twist Bioscience Corporation Evotec SE Sartorius AG Charles River Laboratories International, Inc. Eurofins Scientific SE Recent Developments in the Market:  In January 2023, Hansoh Pharmaceutical Group Company Limited and Biocytogen Pharmaceuticals have announced a partnership, assignment, and exclusive licence agreement for antibodies. In accordance with this contract, Biogen grants Hansoh Pharma a licence to use its human antibody molecules for the global development and production of antibodies. Global Antibody Discovery Market Report Scope:  Historical Data – 2020 - 2021  Base Year for Estimation – 2022  Forecast period - 2023-2030  Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends  Segments Covered – Method, Antibody Type, End User, Region  Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa  Customization Scope - Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope* The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study. The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and Methodofferings of key players. The detailed segments and sub-segment of the market are explained below: By Method: Phage Display Hybridoma Others By Antibody Type: Humanized Antibody Human Antibody Chimeric Antibody Murine Antibody By End User: Pharmaceutical and Biotechnology industry Research laboratory Academic laboratory By Region: North America U.S. Canada Europe UK Germany France Spain Italy ROE Asia Pacific China India Japan Australia South Korea RoAPAC Latin America Brazil Mexico Middle East & Africa Saudi Arabia South Africa Rest of Middle East & Africa